Loading quotes...

Forecast

The analysts' average price target is €618.91 (+3.17%). The median is €634.71 (+5.80%).

Buy	13
Hold	9
Sell	1

News Go to news feed

IDEXX Laboratories reaffirms growth targets, highlights diagnostic pipeline

IDEXX Laboratories reiterated long-term targets of >10% organic revenue growth and >15% EPS growth, driven by recurring revenue and an underpenetrated $45bn veterinary diagnostics market. Management emphasized product momentum—expanding the inVue Dx cytology platform, adding Catalyst tests, broadening Cancer Dx into a multi-cancer panel and developing MultiQ Dx—while expecting ~1.5% fewer veterinary visits in H2 but higher diagnostic utilization from an aging, more medicalized pet population. The company targets a full-year comparable operating margin above 32%, plans continued commercial expansion and R&D investment, and prioritizes organic growth with excess capital returned via share repurchases. » More on finance.yahoo.com
IDEXX presents growth plan at Morgan Stanley conference and bets on diagnostic innovation

IDEXX presented a growth plan at the Morgan Stanley Global Healthcare Conference that offsets a near‑term slight decline in veterinary visits (expected H2‑2026: −1.5 to −2%) with long‑term tailwinds from new diagnostic products and commercial expansion. Management highlighted an "exceptional" Q2, raised the annual guidance, and reaffirmed long‑term targets of over 10% organic growth and more than 15% EPS growth. Key drivers are new products such as Cancer Dx, inVue Dx and the planned MultiQ Dx platform, along with investments in sales, software and international expansion; the operating margin for 2026 is expected to exceed 32%. IDEXX emphasizes high recurring revenue in reference labs, strong test demand, and the use of free cash flow for reinvestment and share buybacks. » More on de.investing.com
Baron Focused Growth highlights IDEXX Laboratories as core health-care holding

In its Q2 2026 investor letter, Baron Focused Growth Fund named IDEXX Laboratories as a key health-care holding, citing its leadership in veterinary diagnostics and benefits from pandemic-driven pet ownership and aging pet demographics. The fund, which returned 13.26% in Q2 while trailing the Russell 2500 Growth, views IDEXX as a competitively advantaged business within a diversified, growth-oriented portfolio. IDEXX closed at $562.20 on August 19, 2026 with a $44.29 billion market cap and has a one‑month return of 4.23% and a 52‑week decline of 11.19%. » More on finance.yahoo.com

Historical dividends Dividends

All dividend metrics All metrics

In 2022, IDEXX Laboratories has already paid €0.0991 in dividends. The last payout was in June 2022.

Financials

In the last quarter, IDEXX Laboratories had revenue of €1.07B and net profit of €296.52M

(EUR)	June 2026	YoY
Revenue	1.07B	13.25%
Gross profit	682.64M	15.82%
Net profit	296.52M	18.88%
EBITDA	410.47M	18.16%

Fundamentals

Metric	Value
Market capitalization	€38.82B
Number of shares	78.78M
52-week high/low	€688.33 - €447.53
Dividends	No
Beta	1.55
P/E ratio	38.71
PEG ratio	2.19
P/B ratio	27.38
P/S ratio	9.54

Company profile

IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

Name	IDEXX Laboratories
CEO	Michael Erickson
Headquarters	Westbrook, me USA
Website	idexx.com
Sector	Health Care
Industry	Health Care Equipment & Supplies
IPO	11/17/2020
Employees	11,000